Alar Pharmaceuticals’ long-acting ketamine shows early potential in TRD

Phase 1positiveAlar's long-acting ketaminePositive

AI Analysis

Summary

Alar Pharmaceuticals' long-acting ketamine demonstrated early potential in treating treatment-resistant depression by mitigating certain adverse events, potentially eliminating the need for post-dose monitoring.

Clinical Trial Data

Phase

early

Outcome Details

Long-acting ketamine showed early potential with mitigation of certain adverse events, potentially eliminating need for post-dose monitoring

Importance:5/10

Sentiment:

0.60

ketaminetreatment-resistant depressionTRDadverse event mitigationlong-acting formulation

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on April 7, 2026 10:25 AM

Read Original